Damora Therapeutics, Inc.
Cash Flow History
| Fiscal Year | Operating Cash Flow | Free Cash Flow | CapEx | Share-Based Compensation |
|---|---|---|---|---|
| FY2023 | $-36.9M | $-36.9M | — | $5.4M |
| FY2024 | $-18.6M | $-18.6M | — | $3.2M |
| FY2025 | $-6.7M | $-6.7M | — | $998.0K |
Cash Flow History
| Fiscal Year | Operating Cash Flow | Free Cash Flow | CapEx | Share-Based Compensation |
|---|---|---|---|---|
| FY2023 | $-36.9M | $-36.9M | — | $5.4M |
| FY2024 | $-18.6M | $-18.6M | — | $3.2M |
| FY2025 | $-6.7M | $-6.7M | — | $998.0K |